CBX-663 for advanced blood cancers, solid tumors, or glioblastoma
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called CBX-663 in people with certain blood cancers, solid tumors, or glioblastoma that have returned or not responded to standard treatment. It aims to see if the drug is safe and helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a specific type of blood cancer (AML, MDS, or CMML), a solid tumor, or glioblastoma that has not responded to treatment or has come back.
- You must have a specific genetic marker called HLA-A*02:01.
- You must be in generally good health (able to do daily activities on your own or with minimal help).
- Your kidney and liver function must be within a certain range.
- You must not have active infections or certain heart conditions, and you must not be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, DXC006, for people with advanced solid tumors or blood cancers like multiple myeloma and neuroblastoma that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called DXC018 for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. The goal is to see if the drug can shrink or slow the growth of these tumors.
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.